Tolterodine Tartrate Tablets

This product is used to relieve the symptoms of frequent urination, urgency and urgency incontinence caused by overactive bladder. It is a competitive M cholinergic receptor blocker. The results of animal experiments indicate that this product has higher selectivity for the bladder than the salivary glands, but this has not yet been clinically confirmed. After oral administration, this product is metabolized by the liver into the active metabolite 5-hydroxymethyl derivative, which has the main pharmacological effect. Its anticholinergic activity is similar to that of this product. Both are highly selective for M cholinergic receptors, and have very weak effects or affinity on receptors of other neurotransmitters and potential cell targets (such as calcium channels).

The main ingredient of this product is (R)-N, N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine L ()-tartrate

This product is a white film-coated tablet, which appears white after removing the film coating.

This product is suitable for the treatment of symptoms of frequent urination, urgency or urgency urinary incontinence caused by overexcited bladder.

The initial recommended dose is 2 mg twice daily. Depending on the patient's response and tolerance, the dose can be lowered to 1 mg twice daily. For patients with hepatic impairment or who are taking CYP3A4 inhibitors (see Drug Interactions), the recommended dose is 1 mg twice daily.

The adverse reactions of this drug are generally tolerable and disappear after stopping the drug. This product can cause mild to moderate anticholinergic effects, such as dry mouth, indigestion and decreased tears. Common (>1/100) Autonomic nervous system: dry mouth Gastrointestinal system: indigestion, constipation, abdominal pain, flatulence, vomiting Systemic: headache Eye: dry eyes Skin: dry skin Mental: drowsiness, nervousness Central nervous system: paresthesia Not very common (<1/100) Autonomic nervous system: dysregulation Systemic: chest pain Rare (1/1000) Systemic: allergic reaction <br

1. Patients with urinary retention, gastric stagnation, and uncontrolled narrow-angle glaucoma are contraindicated. 2. Patients with confirmed allergic reactions to this product are contraindicated. 3. Patients with myasthenia gravis, severe ulcerative colitis, and toxic megacolon are contraindicated.

Precautions for children: There is no experience of using this drug for children, and it is not recommended for children. Precautions for pregnancy and lactation: Pregnant women should use this product with caution, and breastfeeding should be stopped when taking this product during lactation. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference literature.

When co-administered with other drugs with anticholinergic effects, the therapeutic effect can be enhanced but also the adverse reactions. Conversely, muscarinic receptor agonists can reduce the efficacy of this product. Other drugs may interact with this product in pharmacokinetic terms because they require cytochrome P4502D6 (CYP2D6) or CYP3A4 for metabolism or can inhibit cytochrome activity. For example, co-administration with fluoxetine (fluoxetine is a strong inhibitor of CYP2D6, and fluoxetine is metabolized to demethylfluoxetine, which is an inhibitor of CYP3A4) can slightly increase the amount of unbound tolterodine and its 5-hydroxymethyl metabolite, but this does not cause an interaction of obvious clinical significance. If a stronger CYP3A4 inhibitor such as a macrocyclic antibiotic (erythromycin and clomiphene) is to be used in combination

Sealed and stored at room temperature. Valid for 1 year.

1mg

Tentative 12 months

Han Hui Pharmaceuticals Company Limited

• Founded in:

  2012-09-06

• Address:

  No. 2 Haizheng Road, Xukou Town, Fuyang District, Hangzhou City, Zhejiang Province

• Tax NO.:

  91330100053653670B

• Registered Funds:

  1852.03035908 yuan

• Website:

  Log in to view

• Email:

  Log in to view